Trial Profile
A Phase II Study of Apatinib In Combination With Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2020
Price :
$35
*
At a glance
- Drugs Etoposide (Primary) ; Rivoceranib (Primary)
- Indications Carcinoma; Ovarian cancer
- Focus Therapeutic Use
- 03 Dec 2020 Status changed from active, no longer recruiting to completed.
- 13 Jan 2019 Planned End Date changed from 1 Aug 2019 to 30 Jun 2019.
- 13 Jan 2019 Status changed from recruiting to active, no longer recruiting.